Patents Assigned to Institut National de la Sante et de la Recherche Medicale
  • Patent number: 10842635
    Abstract: A temporo-mandibular prosthesis including a glenoid part and a condylar part intended to be articulated relative to the glenoid part. The glenoid part including a glenoid support made in a metallic material; and a glenoid insert made in a non-metal lie material, and defining a seat for a head of said condylar part to define said articulation, wherein the glenoid support defines a housing having an opening through which said glenoid insert is insertable into said housing, said opening opening on an external side (E) of said glenoid support, the glenoid support comprising a tab configurable in a passive position and in an active position in which said tab allows and forbids, respectively, the insertion and the extraction, respectively, of said glenoid insert into and out of said housing, respectively.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: November 24, 2020
    Assignees: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre Hospitalier Regional Universitaire De Lille, Universite De Lille
    Inventor: Joel Ferri
  • Patent number: 10844109
    Abstract: The invention relates to a novel method for the synthesis of an erythrocyte protein, in which said protein is synthesized in an acellular system for the production of proteins, in the presence of at least one detergent which is non-ionic, of liposomes or of nanodiscs. The invention also relates to compositions comprising the proteins produced in this way.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: November 24, 2020
    Assignees: Institut National Transfusion Sanguine, Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Diderot Paris 7
    Inventors: Isabelle Mouro-Chanteloup, Sandrine Genetet
  • Patent number: 10837981
    Abstract: A method of operating an atomic force microscope, comprising a probe, the probe being moved forth and back during respective trace and retrace times of a scan line, the method comprising: a) during trace time, oscillating the probe, b) generating a z feedback signal to keep an amplitude of oscillation of the probe constant at a setpoint value, the z feedback signal being generated by a first feedback loop, c) during retrace time, placing the probe in a drift compensation state by changing the setpoint value to a different value so that the z feedback signal being generated by the first feedback loop causes the probe to move away from the sample and oscillate free, d) detecting an amplitude of free oscillation of the probe and adjusting with a second feedback loop its excitation signal to maintain the amplitude of free oscillation of the probe close to a set value.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: November 17, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE D'AIX-MARSEILLE
    Inventors: Simon Scheuring, Atsushi Miyagi
  • Patent number: 10828342
    Abstract: The present invention relates to a method for preventing Gram-negative bacterial colonization of an oropharyngeal material, the said method comprising bringing into contact a composition comprising a cranberry-derived proanthocyanidin extract on at least a part of the surface area of the said material.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: November 10, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DIDEROT—PARIS 7, ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS
    Inventors: Jean-Damien Ricard, Dimitri Margetis
  • Patent number: 10832089
    Abstract: Provided herein is a method for determining the temporal progression of a biological phenomenon which may affect a studied subject, the method including the steps of providing first data relative to biomarkers for the studied subject, the biomarkers being relative to the progression of the biological phenomenon, providing a numerical model, converting the first data into at least one point on the same Riemann manifold, and using a numerical model to determine a temporal progression for the biological phenomenon for the studied subject, the numerical model being a function in a Riemann manifold, the numerical model associating to values of biomarkers a temporal progression trajectory for the biological phenomenon and data relative to the dispersion of the progression trajectory for the biological phenomenon among a plurality of subjects, the numerical model being obtained by using a stochastic approximation in an expectation-maximization technique on data relative to biomarkers.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: November 10, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE, ECOLE POLYTECHNIQUE, INRIA INSTITUT NATIONAL DE RECHERCHE EN INFORMATIQUE ET AN AUTOMATIQUE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, SORBONNE UNIVERSITÉ, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Stanley Durrleman, Jean-Baptiste Schiratti, Stéphanie Allassonniere, Olivier Colliot
  • Publication number: 20200338062
    Abstract: The present invention relates to the general field of the treatment and prevention of diseases involving an inflammatory condition, namely sepsis or infectious or viral diseases as well as diseases requiring for the of treatment an immunosuppressive activity namely autoimmune diseases and graft rejection. In particular, the invention relates to an inhibitor of the activity or the formation of the PP1/GADD34 complex for the treatment of a condition requiring an immunosuppressive activity or an anti-inflammatory activity.
    Type: Application
    Filed: May 14, 2020
    Publication date: October 29, 2020
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite d'Aix-Marseille
    Inventor: Philippe Pierre
  • Patent number: 10815272
    Abstract: The present invention provides peptides corresponding to fragments of CD31 that inhibit platelet and leukocyte activation, and to their use in the treatment of thrombotic disease. These peptides find use as therapeutic agents in the treatment of inflammatory diseases and thrombotic diseases such as atherothrombosis, in particular when immobilised onto solid supports.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: October 27, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DIDEROT—PARIS 7, UNIVERSITE PARIS 13—PARIS NORD, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Giuseppina Caligiuri, Antonino Nicoletti
  • Patent number: 10815207
    Abstract: The present invention relates to compound of general formula (I) R1 is selected from H, aryl and alkyl, R2 is selected from H, alkyl, aryl and CO—R6; R3 is selected from H, halogen, alkyl, alkenyl, alkynyl, aryl, NHR7, NR7R8, OR7 and SR7; R4 is selected from (C6-C12) alkyl, (C2-C12) alkenyl, (C2-C12) alkynyl and (C6-C10) aryl, R5 represents H, R6, aryl, OH, OR6, O-aryl, SH, SR6, S-aryl, CN, NO2, CF3, COOR6, SO2NR6R7, CONR6R7, NH2, NHR6, NH-aryl, NR6R7, NHCOR6 or aminoacyl; R6 is alkyl optionally substituted with halogen, OH, SH, NH2, O-alkyl, S-alkyl, NH-alkyl or NH-di(alkyl); R7 and R8 identical or different are H or alkyl optionally substituted with halogen, OH, SH, NH2, O-alkyl, S-alkyl, NH-alkyl or NH-di (alkyl), their pharmaceutically acceptable salts and/or isomers, tautomers, solvates or isotopic variations thereof. The compounds are useful for the treatment of cancers.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: October 27, 2020
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Nice Sophia Antipolis, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Stephane Rocchi, Rachid Benhida, Robert Ballotti, Magali Plaisant, Cyril Ronco, Antoine Millet
  • Patent number: 10807958
    Abstract: The present invention relates to the compound having Formula (I) or pharmaceutically acceptable salts or solvates thereof, and its use in treating and/or preventing a Tauopathy.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: October 20, 2020
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE DE LILLE 2 DROIT ET SANTE
    Inventors: Nicolas Sergeant, Luc Buee, Patricia Melnyk, Marion Gay, Nicolas Le Fur
  • Publication number: 20200324408
    Abstract: A medical system comprising: a robotic arm, a control unit configured to issue a control signal, a medical device intended to penetrate an anatomical structure, the medical device being configured to emit a warning signal which varies as a function of a variable electrical characteristic of the anatomical structure, said medical device comprising a body with first and second electrodes, an electric generator suitable for applying at least one measurement electric current between the first and second electrodes, and a processing device suitable for determining a measurement parameter related to the electrical characteristic, based on said at least one measurement electric current, and for emitting the warning signal corresponding to the measurement parameter, wherein the control unit is configured to issue the control signal as a function of the warning signal.
    Type: Application
    Filed: October 24, 2018
    Publication date: October 15, 2020
    Applicants: SPINEGUARD, SORBONNE UNIVERSITE, INSERM (Institut National de la Santé et de la Recherche Médicale), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -
    Inventors: Maurice BOURLION, Olivier FREZAL, Guillaume MOREL, Stéphans BETTE, Thibault CHANDANSON, Florian RICHER, Valentin KERSPERN
  • Patent number: 10801040
    Abstract: The present invention relates to methods and pharmaceutical compositions for expressing a polynucleotide of interest in the peripheral nervous system of a subject. In particular, the present invention relates to a method for selectively expressing a polynucleotide of interest in the peripheral nervous system of a subject in need thereof comprising the step of transducing a peripheral nerve of the subject with an amount of an AVV9 vector containing the polynucleotide of interest.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: October 13, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE PARIS-SUD, COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), UNIVERSITÉ DE MONTPELLIER
    Inventors: Patrick Aubourg, Nicolas Tricaud, Benoît Gautier
  • Patent number: 10793909
    Abstract: The present invention relates to methods for predicting the survival time of patients with decompensated alcoholic cirrhosis. In particular, the present invention relates to a method for predicting the survival time of a patient with decompensated alcoholic cirrhosis comprising i) determining the expression level of OAS2 or MX2 in a sample of peripheral blood mononuclear cells obtained from the patient, ii) comparing the level determined at step i) with a predetermined reference value and iii) and concluding that the patient will have a short survival time when the level determined at step i) is higher than its predetermined reference value or concluding that the patient will have a long survival time when the level determined at step i) is lower than the predetermined reference value.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: October 6, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), UNIVERSITE PARIS DIDEROT—PARIS 7
    Inventors: Richard Moreau, Emmanuel Weiss, Pierre-Emmanuel Rautou
  • Patent number: 10793892
    Abstract: The present invention relates to a method for detecting the presence of expanded-spectrum ß-lactamase (ß-lactamase hydrolyzing expanded-spectrum cephalosporin)-producing bacteria in a sample, said method comprising the steps of: a) performing cell lysis on a test sample in order to obtain an enzymatic suspension; b) reacting a fraction of the enzymatic suspension obtained in step a) with a reagent kit, said reagent kit comprising —expanded-spectrum ß-lactamase substrate selected from the group consisting of cephalosporins, aztreonam, and cephamycins, —a pH color indicator which will change color when the pH of the reaction mixture is comprised between 6.4 and 8.4, wherein a color change after step b) indicates the presence of expanded-spectrum ß-lactamase-producing bacteria in the test sample. The invention also relates to a reagent kit, to a microtiter plate and to their uses in detecting the presence of expanded-spectrum ß-lactamase producers in a test sample.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: October 6, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITÉ PARIS-SACLAY, ASSISTANTE PUBLIQUE HOPITAUX DE PARIS (APHP)
    Inventors: Patrice Nordmann, Laurent Dortet, Laurent Poirel
  • Patent number: 10787506
    Abstract: The present invention relates to a neutralising antibody which is capable of binding to neurotensin with high affinity. The antibody of the present invention neutralises the activity of neurotensin, in particular the oncogenic activities of neurotensin. In particular, the present invention relates to a neutralising antibody which binds to the human neurotensin long fragment, and having a heavy chain variable region which comprises a H-CDR1 region having at least 90% of identity with SEQ ID NO:2, a H-CDR2 region having at least 90% of identify with SEQ ID NO:3 and a H-CDR3 region having at least 90% of identity with SEQ ID NO:4; and a light chain variable region comprising a L-CDR1 region having at least 90% of identity with SEQ ID NO:6, a L-CDR2 having at least 90% of identity with SEQ ID NO:7 and a L-CDR3 region having at least 90% of identity with SEQ ID NO:8. The present invention also provides the use of such antibodies in the treatment of cancer.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: September 29, 2020
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paris Descartes
    Inventor: Patricia Forgez
  • Publication number: 20200297799
    Abstract: The invention features methods of using SFGFR3 polypeptides to treat abnormal visceral fat deposition and the conditions associated with abnormal visceral fat deposition.
    Type: Application
    Filed: September 20, 2018
    Publication date: September 24, 2020
    Applicants: Pfizer Inc., Université Côte d'Azur, INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National de la Recherche Scientifique
    Inventors: Elvire Gouze, Stéphanie Garcia
  • Patent number: 10781452
    Abstract: The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: September 22, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIER
    Inventor: Jean Valmier
  • Patent number: 10782304
    Abstract: The present invention relates to methods and kits for detection protein-protein interactions.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: September 22, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ PAUL SABATIER TOULOUSE III
    Inventors: Stéphanie Cabantous, Faten Koraïchi, Gilles Favre
  • Publication number: 20200291466
    Abstract: The invention relates to a method for detecting a mutation in a microsatellite sequence locus of a target fragment from a DNA sample, comprising subjecting said DNA sample to a digital polymerase chain reaction (PCR) in the presence of a PCR solution comprising: a pair of primers for amplifying said target fragment of the DNA sample including said microsatellite sequence; a first MS oligonucleotide (MS) hydrolysis probe, labeled with a first fluorophore, wherein said first MS oligonucleotide probe is complementary to a wild-type sequence including the microsatellite sequence; a second oligonucleotide reference (REF) hydrolysis probe, labeled with a second fluorophore, wherein said second oligonucleotide REF probe is complementary to a wild-type sequence of said target DNA fragment which does not include said microsatellite sequence. The invention also encompasses methods for the diagnosis and prognosis of cancer and a method for determining the efficacy of a cancer treatment.
    Type: Application
    Filed: July 11, 2018
    Publication date: September 17, 2020
    Applicants: Institut Curie, Institut National de la Santé et de la Recherche Médicale, Universite de Versailles Saint-Quentin-en-Yvelines
    Inventors: Charlotte PROUDHON, Amélie KASPEREK, Amanda BORTOLINI SILVEIRA, François-Clément BIDARD, Marc-Henri STERN
  • Patent number: 10774153
    Abstract: The present invention relates to compositions and methods for modulating angiogenesis in vivo, ex vivo or in vitro. More particularly, the invention relates to a soluble CD146 protein usable in the context of human therapy, as well as to corresponding antibodies. Particular forms of CD146, herein described, may be used to mobilize, in vivo or ex vivo, both mature and immature endothelial cells, as well as to increase their influence on angiogenesis. The invention also relates to compositions comprising such compounds, particularly pharmaceutical or diagnostic compositions, including kits and the like, as well as methods of therapy or diagnosis using said compounds, compositions and cells.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: September 15, 2020
    Assignees: UNIVERSITE D'AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Marcel Blot-Chabaud, Karim Harhouri, Nathalie Bardin, Benjamin Guillet, Francoise Dignat-George
  • Patent number: 10775387
    Abstract: The present invention relates to various soluble forms of CD31, including a novel form which is shed by activated platelets and released into the circulation. Methods for detecting said soluble forms of CD31 are disclosed, as are methods of specifically 1 detecting said platelet-derived shed CD31 and the use of such methods as a diagnostic tool.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: September 15, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE PARIS, UNIVERSITE PARIS 13—PARIS NORD, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Giuseppina Caligiuri, Antonino Nicoletti